JP2022519796A5 - - Google Patents

Info

Publication number
JP2022519796A5
JP2022519796A5 JP2021523466A JP2021523466A JP2022519796A5 JP 2022519796 A5 JP2022519796 A5 JP 2022519796A5 JP 2021523466 A JP2021523466 A JP 2021523466A JP 2021523466 A JP2021523466 A JP 2021523466A JP 2022519796 A5 JP2022519796 A5 JP 2022519796A5
Authority
JP
Japan
Prior art keywords
approximately
antibody
amino acid
acid sequence
concentration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523466A
Other languages
English (en)
Japanese (ja)
Other versions
JP7502286B2 (ja
JP2022519796A (ja
Filing date
Publication date
Priority claimed from CN201811283440.7A external-priority patent/CN111110841A/zh
Application filed filed Critical
Publication of JP2022519796A publication Critical patent/JP2022519796A/ja
Publication of JP2022519796A5 publication Critical patent/JP2022519796A5/ja
Application granted granted Critical
Publication of JP7502286B2 publication Critical patent/JP7502286B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523466A 2018-10-31 2019-10-30 抗pcsk9抗体を含む安定製剤 Active JP7502286B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811283440.7A CN111110841A (zh) 2018-10-31 2018-10-31 含有抗pcsk9抗体的稳定制剂
CN201811283440.7 2018-10-31
PCT/CN2019/114233 WO2020088492A1 (zh) 2018-10-31 2019-10-30 含有抗pcsk9抗体的稳定制剂

Publications (3)

Publication Number Publication Date
JP2022519796A JP2022519796A (ja) 2022-03-25
JP2022519796A5 true JP2022519796A5 (cg-RX-API-DMAC7.html) 2022-10-24
JP7502286B2 JP7502286B2 (ja) 2024-06-18

Family

ID=70464340

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523466A Active JP7502286B2 (ja) 2018-10-31 2019-10-30 抗pcsk9抗体を含む安定製剤

Country Status (6)

Country Link
US (1) US20210393777A1 (cg-RX-API-DMAC7.html)
EP (1) EP3878467A4 (cg-RX-API-DMAC7.html)
JP (1) JP7502286B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210096105A (cg-RX-API-DMAC7.html)
CN (3) CN111110841A (cg-RX-API-DMAC7.html)
WO (1) WO2020088492A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022037606A1 (en) * 2020-08-19 2022-02-24 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases
CN114344460B (zh) * 2020-10-13 2025-09-19 信立泰(成都)生物技术有限公司 含有抗pcsk9抗体的稳定制剂及其制备方法和用途
EP4548931A1 (en) * 2022-06-30 2025-05-07 AD Pharmaceuticals Co., Ltd. Anti-pcsk9 antibody preparation and use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
PL3721904T3 (pl) * 2009-11-20 2022-01-31 Biocon Limited Formulacje przeciwciała t1h
SI3409289T1 (sl) * 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
EA039663B1 (ru) * 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
CN108025072A (zh) * 2015-09-22 2018-05-11 辉瑞公司 制备治疗用蛋白质制剂的方法和由这种方法生产的抗体制剂
CN106810609A (zh) * 2015-11-27 2017-06-09 苏州君盟生物医药科技有限公司 抗pcsk9抗体及其应用

Similar Documents

Publication Publication Date Title
JP2020518599A5 (cg-RX-API-DMAC7.html)
RU2722643C2 (ru) Способ лечения болезней глаз
JP2017536414A5 (cg-RX-API-DMAC7.html)
JP2020138981A5 (cg-RX-API-DMAC7.html)
JP2022532927A5 (cg-RX-API-DMAC7.html)
JP2023515271A5 (cg-RX-API-DMAC7.html)
JP2015526440A5 (cg-RX-API-DMAC7.html)
RU2012131099A (ru) Препарат антитела
JP2017160208A5 (cg-RX-API-DMAC7.html)
JP6405406B2 (ja) 生物学的治療薬およびグアニジンまたはグアニジン誘導体を含む水性医薬組成物、並びに該組成物を含む注射剤
RU2006120950A (ru) Антитело к cd40: препарат и способы
JP2013500947A5 (cg-RX-API-DMAC7.html)
JP2025090691A5 (cg-RX-API-DMAC7.html)
RU2015111341A (ru) Композиции антитела и белка
CN113797333A (zh) 一种新型冠状病毒抗体的药物组合物及其用途
JP2024538140A5 (cg-RX-API-DMAC7.html)
JP2020532562A5 (cg-RX-API-DMAC7.html)
JP2024531151A5 (cg-RX-API-DMAC7.html)
CL2024000232A1 (es) Composición farmacéutica de anticuerpo anti-pd-1 y uso de la misma
CN114762678B (zh) 抗tigit抗体药物组合物及其用途
RU2020112302A (ru) Соединения для уменьшения вязкости биологических композиций
JP2022512704A5 (cg-RX-API-DMAC7.html)
JP2023540025A5 (cg-RX-API-DMAC7.html)
JP2024515968A5 (cg-RX-API-DMAC7.html)
RU2018129077A (ru) Стабильная фармацевтическая композиция